Clinical drug development is moving away from traditional approaches that rely on rare disease patients to travel long distances to clinical sites and toward a more patient-focused paradigm, one that highlights virtual and decentralized clinical trials (DCT). By bringing trials directly to patients instead of requiring patients to travel to sites, we can alleviate a primary burden of clinical trial participation and democratize clinical trial access. In this white paper, you’ll learn the following key points:
- How the new research model can increase access to trials, allowing us to bring new therapies to rare disease patients faster.
- How practical strategies for easing patient participation burdens will aid in transitioning from traditional site-based paradigms to more patient-focused virtual or DCT models.
- What considerations must be made to select technology that seamlessly integrates clinical trials into patients’ lives.
Innovative Technology Solution for a 15 Year Rare Disease Gene Therapy Registry
A Top 10 pharmaceutical client required a mobile technology solution to collect safety and effectiveness data on a groundbreaking treatment for an…
Two PRA Teams to Participate at PHUSE/FDA Data Science Innovation Challenge
What if we could join forces with some of our industry’s most exceptional minds to revolutionize the way the world thinks about healthcare? Every…
Machine Learning and Pattern Recognition Models Help Fill in the Gaps of Drug-Drug Interactions
Many individuals, particularly in elderly populations, take a variety of prescription and over-the-counter medicines and dietary supplements each…